|
DCF -Bewertung von Entrada Therapeutics, Inc. (TRDA)
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Entrada Therapeutics, Inc. (TRDA) Bundle
Erforschen Sie die Finanzaussichten für Entrada Therapeutics, Inc. (TRDA) mit unserem benutzerfreundlichen DCF-Taschenrechner! Geben Sie Ihre Prognosen für Wachstum, Margen und Ausgaben ein, um die Intrinsische Wert von Entrada Therapeutics, Inc. (TRDA) zu berechnen und Ihre Anlageentscheidungen zu informieren.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | 129.0 | 210.8 | 244.2 | 282.9 | 327.7 | 379.6 | 439.8 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 63.38 | 15.85 | 15.85 | 15.85 | 15.85 | 15.85 |
| EBITDA | -26.3 | -50.0 | -95.4 | -.3 | 47.0 | 157.3 | 182.2 | 211.1 | 244.5 | 283.3 |
| EBITDA, % | 100 | 100 | 100 | -0.24881 | 22.3 | 64.41 | 64.41 | 64.41 | 64.41 | 64.41 |
| Depreciation | .3 | 1.1 | 1.9 | 2.8 | .0 | 147.6 | 171.0 | 198.1 | 229.4 | 265.8 |
| Depreciation, % | 100 | 100 | 100 | 2.2 | 0 | 60.44 | 60.44 | 60.44 | 60.44 | 60.44 |
| EBIT | -26.7 | -51.1 | -97.2 | -3.2 | 47.0 | 156.2 | 181.0 | 209.6 | 242.8 | 281.3 |
| EBIT, % | 100 | 100 | 100 | -2.45 | 22.3 | 63.97 | 63.97 | 63.97 | 63.97 | 63.97 |
| Total Cash | 39.0 | 291.1 | 45.2 | 352.0 | 420.0 | 244.2 | 282.9 | 327.7 | 379.6 | 439.8 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | 5.9 | 3.7 | 149.6 | 173.3 | 200.7 | 232.6 | 269.4 |
| Account Receivables, % | 100 | 100 | 100 | 4.56 | 1.75 | 61.26 | 61.26 | 61.26 | 61.26 | 61.26 |
| Inventories | .0 | .0 | .0 | .0 | .0 | 146.5 | 169.7 | 196.6 | 227.8 | 263.9 |
| Inventories, % | 100 | 100 | 100 | 0 | 0 | 60 | 60 | 60 | 60 | 60 |
| Accounts Payable | 1.6 | .7 | 6.0 | 3.3 | 4.3 | 148.7 | 172.3 | 199.6 | 231.2 | 267.9 |
| Accounts Payable, % | 100 | 100 | 100 | 2.54 | 2.02 | 60.91 | 60.91 | 60.91 | 60.91 | 60.91 |
| Capital Expenditure | -2.3 | -4.6 | -2.9 | -5.6 | -3.2 | -2.9 | -3.3 | -3.8 | -4.4 | -5.1 |
| Capital Expenditure, % | 100 | 100 | 100 | -4.35 | -1.5 | -1.17 | -1.17 | -1.17 | -1.17 | -1.17 |
| Tax Rate, % | 1.29 | 1.29 | 1.29 | 1.29 | 1.29 | 1.29 | 1.29 | 1.29 | 1.29 | 1.29 |
| EBITAT | -26.5 | -50.0 | -89.9 | 1.8 | 46.4 | 121.4 | 140.6 | 162.9 | 188.7 | 218.6 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -26.9 | -54.4 | -85.6 | -9.6 | 46.4 | 118.2 | 284.9 | 330.0 | 382.3 | 442.9 |
| WACC, % | 4.87 | 4.86 | 4.83 | 4.41 | 4.86 | 4.77 | 4.77 | 4.77 | 4.77 | 4.77 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 1,327.7 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 452 | |||||||||
| Terminal Value | 16,333 | |||||||||
| Present Terminal Value | 12,941 | |||||||||
| Enterprise Value | 14,268 | |||||||||
| Net Debt | -42 | |||||||||
| Equity Value | 14,310 | |||||||||
| Diluted Shares Outstanding, MM | 39 | |||||||||
| Equity Value Per Share | 366.90 |
What You Will Get
- Real TRDA Financial Data: Pre-filled with Entrada Therapeutics’ historical and projected data for precise analysis.
- Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
- Automatic Calculations: See Entrada Therapeutics’ intrinsic value update instantly based on your changes.
- Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
- User-Friendly Design: Simple structure and clear instructions for all experience levels.
Key Features
- Comprehensive Entrada Data: Gain access to reliable pre-loaded historical performance metrics and future forecasts.
- Adjustable Forecast Parameters: Modify highlighted fields such as WACC, growth rates, and profit margins.
- Real-Time Calculations: Automatic updates for DCF, Net Present Value (NPV), and cash flow assessments.
- User-Friendly Dashboard: Clear charts and summaries designed to help visualize your valuation outcomes.
- Suitable for All Users: An intuitive layout tailored for investors, CFOs, and consultants alike.
How It Works
- Step 1: Download the Excel file for Entrada Therapeutics, Inc. (TRDA).
- Step 2: Review Entrada’s pre-filled financial data and projections.
- Step 3: Adjust key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model update in real-time as you modify your assumptions.
- Step 5: Evaluate the outputs and leverage the results for your investment choices.
Why Choose This Calculator for Entrada Therapeutics, Inc. (TRDA)?
- User-Friendly Interface: Perfectly crafted for both novices and seasoned professionals.
- Customizable Inputs: Adjust parameters effortlessly to suit your specific analysis.
- Real-Time Feedback: Observe immediate updates to Entrada Therapeutics' valuation as you modify inputs.
- Pre-Loaded Data: Comes equipped with Entrada’s current financial metrics for swift evaluations.
- Relied Upon by Experts: A go-to tool for investors and analysts aiming to make educated decisions.
Who Should Use This Product?
- Biotech Students: Understand drug development processes and apply them using real-world data.
- Researchers: Integrate advanced therapeutic models into academic studies or clinical research.
- Investors: Evaluate your investment strategies and analyze market trends for Entrada Therapeutics, Inc. (TRDA).
- Industry Analysts: Enhance your analysis with a comprehensive, customizable valuation model tailored for biotech companies.
- Pharmaceutical Entrepreneurs: Learn how established biotech firms like Entrada Therapeutics are assessed and valued.
What the Template Contains
- Comprehensive DCF Model: Editable template with detailed valuation calculations tailored for Entrada Therapeutics, Inc. (TRDA).
- Real-World Data: Entrada’s historical and projected financials preloaded for in-depth analysis.
- Customizable Parameters: Adjust WACC, growth rates, and tax assumptions to explore various scenarios.
- Financial Statements: Complete annual and quarterly breakdowns for enhanced insights.
- Key Ratios: Integrated analysis for profitability, efficiency, and leverage metrics.
- Dashboard with Visual Outputs: Visualizations including charts and tables for clear, actionable results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.